JP2019519599A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519599A5
JP2019519599A5 JP2019510577A JP2019510577A JP2019519599A5 JP 2019519599 A5 JP2019519599 A5 JP 2019519599A5 JP 2019510577 A JP2019510577 A JP 2019510577A JP 2019510577 A JP2019510577 A JP 2019510577A JP 2019519599 A5 JP2019519599 A5 JP 2019519599A5
Authority
JP
Japan
Prior art keywords
alkyl
disease
halo
independently
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019510577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519599A (ja
JP7003114B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/031367 external-priority patent/WO2017193041A1/en
Publication of JP2019519599A publication Critical patent/JP2019519599A/ja
Publication of JP2019519599A5 publication Critical patent/JP2019519599A5/ja
Application granted granted Critical
Publication of JP7003114B2 publication Critical patent/JP7003114B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019510577A 2016-05-05 2017-05-05 統合ストレス経路のモジュレーター Expired - Fee Related JP7003114B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332280P 2016-05-05 2016-05-05
US62/332,280 2016-05-05
PCT/US2017/031367 WO2017193041A1 (en) 2016-05-05 2017-05-05 Modulators of the integrated stress pathway

Publications (3)

Publication Number Publication Date
JP2019519599A JP2019519599A (ja) 2019-07-11
JP2019519599A5 true JP2019519599A5 (enExample) 2020-06-25
JP7003114B2 JP7003114B2 (ja) 2022-01-20

Family

ID=58710118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019510577A Expired - Fee Related JP7003114B2 (ja) 2016-05-05 2017-05-05 統合ストレス経路のモジュレーター

Country Status (12)

Country Link
US (2) US10836725B2 (enExample)
EP (1) EP3452453B1 (enExample)
JP (1) JP7003114B2 (enExample)
CN (1) CN109689628A (enExample)
AR (1) AR108393A1 (enExample)
AU (1) AU2017260374B2 (enExample)
CA (1) CA3023164A1 (enExample)
ES (1) ES2923875T3 (enExample)
MA (1) MA44866A (enExample)
TW (1) TW201808903A (enExample)
UY (1) UY37229A (enExample)
WO (1) WO2017193041A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094233B (zh) 2017-08-09 2024-03-15 戴纳立制药公司 化合物、组合物及方法
PT3676297T (pt) 2017-09-01 2023-08-29 Denali Therapeutics Inc Compostos, composições e métodos
UY37958A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
UY37956A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
KR20200092332A (ko) * 2017-11-02 2020-08-03 칼리코 라이프 사이언시스 엘엘씨 통합된 스트레스 경로의 조절제
RU2020122711A (ru) 2017-12-13 2022-01-17 ПРАКСИС БАЙОТЕК ЭлЭлСи Ингибиторы пути интегрированной реакции на стресс
SG11202011014VA (en) 2018-06-05 2020-12-30 Praxis Biotech LLC Inhibitors of integrated stress response pathway
JP2021529814A (ja) * 2018-07-09 2021-11-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 化学化合物
TWI832295B (zh) * 2018-10-11 2024-02-11 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
MA54959A (fr) 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés
CA3129609A1 (en) * 2019-02-13 2020-08-20 Denali Therapeutics Inc. Eukaryotic initiation factor 2b modulators
KR20210134351A (ko) * 2019-02-25 2021-11-09 프락시스 바이오테크 엘엘씨 통합 스트레스 반응 경로의 억제제
EA202192900A1 (ru) 2019-04-23 2022-03-18 Эвотек Интернешнл Гмбх Модуляторы пути интегрированной реакции на стресс
AU2020261234A1 (en) 2019-04-23 2021-11-11 Evotec International Gmbh Modulators of the integrated stress response pathway
CA3142748A1 (en) 2019-06-12 2020-12-17 Praxis Biotech LLC Modulators of integrated stress response pathway
KR20220133252A (ko) 2020-01-28 2022-10-04 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절자
JP2023517944A (ja) 2020-03-11 2023-04-27 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 統合的ストレス応答経路の調節因子
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US20230391763A1 (en) 2020-10-22 2023-12-07 Evotec International Gmbh Modulators of the integrated stress response pathway
AU2021366303A1 (en) 2020-10-22 2023-06-22 Evotec International Gmbh Modulators of the integrated stress response pathway
CA3195290A1 (en) * 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
JP2007517868A (ja) 2004-01-07 2007-07-05 アストラゼネカ アクチボラグ 治療薬i
AU2005212073B2 (en) * 2004-02-18 2010-07-08 Kyorin Pharmaceutical Co., Ltd. Bicyclic amide derivatives
US7217838B2 (en) * 2005-01-05 2007-05-15 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
RU2442771C2 (ru) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Производные бицикло[2,2,1]гепт-7-иламина и их применения
WO2011087758A1 (en) 2009-12-22 2011-07-21 H. Lundbeck A/S Adamantyl amide derivatives and uses of same
AR084457A1 (es) 2010-12-22 2013-05-15 Lundbeck & Co As H Derivados de biciclo[3,2,1]octilamida
AU2014233520B2 (en) 2013-03-15 2019-02-21 The Regents Of The University Of California Modulators of the eIF2alpha pathway
WO2015038778A1 (en) 2013-09-11 2015-03-19 The Brigham And Women's Hospital, Inc. SUBSTITUTED UREA EIF2α KINASE ACTIVATORS

Similar Documents

Publication Publication Date Title
JP2019519599A5 (enExample)
JP2019515042A5 (enExample)
JP2019515043A5 (enExample)
JP2019530649A5 (enExample)
RU2018142740A (ru) Модуляторы интегрированного сигнального пути стресса
HRP20210252T1 (hr) Heterociklički amidi kao inhibitori kinaze
JP2013525433A5 (enExample)
JP2019508407A5 (enExample)
JP2009534407A5 (enExample)
PH12020500127A1 (en) Compounds and compositions for treating conditions associated with nlrp activity
AU2020355358A1 (en) PROTAC small molecule compound and application thereof
JP2021501789A5 (enExample)
JP2009534406A5 (enExample)
WO2015101928A1 (en) Fused thiophene and thiazole derivatives as ror gamma modulators
AU2019217320B2 (en) Steroid derivative regulators, method for preparing the same, and uses thereof
JP2013515074A5 (enExample)
IL226912A (en) The history of triazole, their preparation and their pharmaceutical preparations
CA2797663A1 (en) Compounds that modulate intracellular calcium
JP2021501781A5 (enExample)
EP3829561A1 (en) Substituted-3h-imidazo[4,5-c]pyridine and 1h pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (enpp1) and stimulator for interferon genes (sting) modulators as cancer immunotherapeutics
JP2013530236A5 (enExample)
MX2011006343A (es) Tiazoles como ligandos del receptor de cannabinoide.
CN114729044B (zh) 毒蕈碱型乙酰胆碱m1受体拮抗剂
AU2004215481A1 (en) Pyrazolo(1,5-A)pyrimidine derivatives
JP2023085290A (ja) PI3K-γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体